Through RNA-seq analysis, LC-MS evaluation, and in vitro and in vivo experiments, we demonstrated that knocking down PDIA5 expression significantly impaired the malignant phenotypes of GBM via the PDIA5/CCAR1 signaling axis. This evidence concerns the gene CCAR1 and glioblastoma.